Tuesday 13 October 2026
Export ARVN’s income statement to Excel — free account
Arvinas, Inc.
ARVN Healthcare Biotechnology
Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 1,014.7%, EPS grew 410.7%, free cash flow grew 49.8% and total debt fell 40.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.27
0.18
−2.42%
Follow ARVN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
63.92 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.70 | 7.59 | 3.20 | 2.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(11.15) | (9.80) | (27.66) | (10.55) | |
P/B ratio |
0.96 | 1.75 | 1.94 | 1.11 | |
Price to Tangible BV |
0.96 | 1.75 | 1.94 | 1.11 | |
EV/Sales |
(0.09) | 0.73 | 0.60 | (0.52) | |
EV/EBITDA |
1.56 | 0.00 | 0.00 | 1.53 | |
EV/Operating CF |
0.13 | (0.26) | (0.57) | 0.50 | |
EV/FCF |
0.13 | (0.25) | (0.57) | 0.49 | |
Quick Ratio |
7.54 | 5.36 | 4.85 | 5.62 | |
Current Ratio |
7.91 | 5.44 | 4.92 | 5.70 | |
Net Debt/EBITDA |
(3.40) | 9.59 | 9.06 | 17.42 | |
Debt/Assets |
0.04% | 0.05% | 0.06% | 0.05% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.40 | 0.11 | 0.29 | 0.31 | |
Operating CF/Net income |
(0.29) | 1.20 | 0.45 | 1.68 | |
Capex/Depreciation |
(0.07) | 4.33 | 0.20 | 0.07 | |
Research and Development Expense of Revenue |
21.07% | 386.54% | 643.16% | 154.42% | |
Selling, General and Administrative Expense of Revenue |
9.61% | 122.44% | 242.11% | 50.12% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2.36% | 77.56% | 89.47% | 24.34% | |
Graham Net Nets |
1.00 | 0.55 | 0.50 | 0.88 | |
Graham Number |
5.04 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
1.56% | (31.32%) | (10.79%) | (9.51%) | |
Free Cash Flow Yield |
(38.78%) | (37.87%) | (32.79%) | (52.83%) | |
Revenue per Share |
3.85 | 0.24 | 0.13 | 0.57 | |
Operating CF per Share |
(0.75) | (1.08) | (0.43) | (0.81) | |
Capex per Share |
0.00 | (0.02) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.75) | (1.10) | (0.43) | (0.81) | |
Cash per Share |
8.76 | 9.61 | 9.67 | 10.76 | |
Shareholders Equity per Share |
8.68 | 6.04 | 6.12 | 7.71 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.68 | 6.04 | 6.12 | 7.71 | |
Free Cash Flow |
(48.50) | (70.50) | (30.60) | (59.20) | |
Working Capital |
569.70 | 514.80 | 558.20 | 681.40 | |
Capital Expenditures |
(0.20) | (1.30) | (0.20) | (0.10) | |
Net Current Asset Value |
539.30 | 370.00 | 416.70 | 546.40 | |
EV/EBIT |
1.54 | 0.00 | 0.00 | 1.59 | |
Capex to Sales |
0.00 | 0.08 | 0.02 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
32.70 | 7.40 | 10.05 | 20.80 | |
Average Payables |
52.65 | 66.70 | 70.65 | 65.70 | |
Average Assets |
792.20 | 824.30 | 904.65 | 1,005.70 | |
Average Common Equity |
585.75 | 523.45 | 497.80 | 575.20 |
Columns are period end dates